Syngene International Ltd. (NSE: SYNGENE, BSE: 539268) is a Bengaluru, Karnataka-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹17,630 Cr, it ranks #401 by market cap among the 6,197 Indian listed companies on FinBizNet, and #6 of 11 in Pharmaceutical CDMO and CRO Services. At ₹443.00 (as of 16 Nov 2026), the share price is 34.8% below its 52-week high of ₹678.95 and 28.6% above its 52-week low of ₹344.45. The share price is down 27.9% over one year and up 10.7% over three months.
| Current Price | ₹443.00 |
|---|---|
| Market Cap | ₹17,630 Cr |
| NSE Symbol | SYNGENE |
| BSE Code | 539268 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 56.9 |
| Return on Equity | 6.62% |
| Return on Assets | 4.78% |
| 52-Week Range | ₹344.45 – ₹678.95 |
| 1-Year Price Change | -27.9% |
| 3-Month Price Change | +10.7% |
| Beta (1Y) | -0.14 |
| Dividend Yield | 0.28% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.syngeneintl.com |
| Revenue | ₹833 Cr |
|---|---|
| Net Profit | ₹32 Cr |
| Net Margin | 3.9% |
| EPS (Basic) | ₹0.80 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Syngene International Ltd. reported revenue of ₹833 Cr in Q2 FY27, down 8.6% from ₹911 Cr in Q2 FY26 and up 13.1% from ₹736 Cr in Q1 FY27. It posted a net profit of ₹32 Cr for the quarter, against a net profit of ₹67 Cr in Q2 FY26 (down 52.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹736 Cr (Q1 FY27) to ₹1,037 Cr (Q4 FY26). The company reported a net loss in 1 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹833 Cr | ₹32 Cr | 3.9% |
| Q1 FY27 | ₹736 Cr | −₹9 Cr | −1.2% |
| Q4 FY26 | ₹1,037 Cr | ₹148 Cr | 14.3% |
| Q3 FY26 | ₹917 Cr | ₹15 Cr | 1.6% |
| Q2 FY26 | ₹911 Cr | ₹67 Cr | 7.4% |
| Q1 FY26 | ₹875 Cr | ₹87 Cr | 9.9% |
| Q4 FY25 | ₹1,018 Cr | ₹183 Cr | 18.0% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 52.59% of Syngene International Ltd.'s shares as of Sept 2026, against 52.68% in Sept 2025 (−0.09 percentage points). Delivery averaged 47.2% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigil
1. Providing Contract Research and Manufacturing Services-This segment provides contract research and manufacturing services. It offers drug discovery, development, and manufacturing services.
1. Providing Contract Research and Manufacturing Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹3,01,758 Cr | 118.4 | 16.19% | ₹3,676 Cr | +71.9% |
| Anthem Biosciences Limited | ₹53,926 Cr | 90.1 | 19.45% | ₹594 Cr | +34.5% |
| Sai Life Sciences Limited | ₹40,755 Cr | 116.1 | 15.13% | ₹659 Cr | +120.3% |
| Onesource Specialty Pharma Limited | ₹18,138 Cr | n/m | -1.26% | ₹516 Cr | -9.4% |
| Cohance Lifesciences Ltd | ₹17,756 Cr | 100.6 | 5.11% | ₹477 Cr | -35.2% |
| Syngene International Ltd. | ₹17,630 Cr | 56.9 | 6.62% | ₹833 Cr | -27.9% |
| Jubilant Pharmova Ltd | ₹15,556 Cr | 39.1 | 5.96% | ₹2,370 Cr | -14.5% |
| Concord Biotech Ltd | ₹12,495 Cr | 24.2 | 13.54% | ₹309 Cr | -14.8% |
| Blue Jet Healthcare Ltd | ₹10,140 Cr | 38 | 19.88% | ₹376 Cr | -9.8% |
Listed by market capitalisation. Ratios are shown for context only.
Syngene International Ltd. is trading at ₹443.00, with a market capitalisation of ₹17,630 Cr.
Syngene International Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Syngene International Ltd. has a P/E of 56.9 and a return on equity of 6.62%.
Syngene International Ltd. is listed on the NSE under the symbol SYNGENE and on the BSE under the scrip code 539268.
Syngene International Ltd.'s share price is down 27.9% over one year and up 10.7% over three months. Its 52-week range is ₹344.45 to ₹678.95.
In Q2 FY27, Syngene International Ltd. reported revenue of ₹833 Cr and net profit of ₹32 Cr, with basic EPS of ₹0.8 (consolidated, parsed from the company's exchange filing).
Syngene International Ltd. reported revenue of ₹833 Cr in Q2 FY27, down 8.6% from ₹911 Cr in Q2 FY26 and up 13.1% from ₹736 Cr in Q1 FY27.
Promoters held 52.59% of Syngene International Ltd.'s shares as of Sept 2026, against 52.68% in Sept 2025 (−0.09 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.